

Appl. No. 10/051,952
Reply to Office Action of May 28, 2004

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Previously presented) A method for treating a wrinkle in a human subject, the method comprising the step of administering an amount of a botulinum toxin to the human subject using a needleless syringe, the amount of the botulinum toxin being effective to treat the wrinkle by reducing a muscle contraction.
2. (Previously presented) The method of claim 1 wherein the botulinum toxin is administered with a carrier.
3. (Previously presented) The method of claim 2 wherein the botulinum toxin is coated on said carrier.
4. (Currently amended) The method of claim 2 wherein said carrier comprises a ~~dense, preferably solid or metallic,~~ material selected from the group consisting of gold, platinum, tungsten and ice crystal.
5. (Cancelled)
6. (Previously presented) The method of claim 1 wherein the botulinum toxin is administered to a skin of said subject.

Appl. No. 10/051,952
Reply to Office Action of May 28, 2004

7. (Previously presented) The method of claim 1 wherein the botulinum toxin is administered to one or more layers of a skin of said subject where a nerve is located.

8. (Cancelled)

9. (Previously presented) The method of claim 1 wherein the botulinum toxin is administered to a muscle tissue of said subject.

10. (Previously presented) The method of claim 1, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C₁, D, E, F, and G.

11. (Cancelled)

12. (Previously presented) The method of claim 1 wherein the botulinum toxin is botulinum toxin type A.

13-35. (Cancelled)

36. (Previously presented) A method for treating brow furrows in a human subject, the method comprising the step of administering an amount of a botulinum toxin to the human subject using a needleless syringe, the amount of the botulinum toxin being effective to treat a brow furrow by reducing a muscle contraction.

37. (Previously presented) The method of claim 36, wherein the botulinum toxin is administered with a carrier.

Appl. No. 10/051,952
Reply to Office Action of May 28, 2004

38. (Previously presented) The method of claim 37, wherein the botulinum toxin is coated on said carrier.
39. (Previously presented) The method of claim 37, wherein said carrier comprises a dense, preferably solid or metallic, material selected from the group consisting of gold, platinum, tungsten and ice crystal.
40. (Previously presented) The method of claim 36, wherein the botulinum toxin is administered to a skin of said subject.
41. (Previously presented) The method of claim 36, wherein the botulinum toxin is administered to one or more layers of a skin of said subject where a nerve is located.
42. (Previously presented) The method of claim 36, wherein the botulinum toxin is administered to a muscle tissue of said subject.
43. (Previously presented) The method of claim 36, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C₁, D, E, F, and G.
44. (Previously presented) The method of claim 36, wherein the botulinum toxin is botulinum toxin type A.